Home/Pipeline/Trichostatin A (TSA)

Trichostatin A (TSA)

Hematologic Malignancies

DevelopmentActive

Key Facts

Indication

Hematologic Malignancies

Phase

Development

Status

Active

Company

vanda-pharmaceuticals

About vanda-pharmaceuticals

Vanda Pharmaceuticals is a publicly traded biopharma company with a mission to 'innovate in the service of people's pursuit of happiness' by developing targeted therapies for CNS and sleep disorders. Its core strategy integrates genetics and genomics into all stages of drug development to enhance clinical trial success and commercial positioning. Key achievements include the FDA approvals of Fanapt® for schizophrenia and Hetlioz® for Non-24, with recent milestones including the 2026 approval of BYSANTI™ and a landmark FDA hearing for Hetlioz® in Jet Lag Disorder.

View full company profile

Therapeutic Areas

Neuropsychiatry Sleep-Wake Disorders Dermatology Oncology

Other Hematologic Malignancies Drugs

Drug	Company	Phase	Status
CER-T Cell Platform	cero-therapeutics	Pre-clinical	Research & Development
Not Specified (Hematologic Malignancies)	abelzeta-pharma	Clinical	Active
PredicineHEME™	Predicine	Commercial	Active
Orca-T	bristol-myers-squibb	Phase 3	Active
NK‑Thera	vectorite-biomedical	Phase 1/2	Active
DARIC-NK Program	coeptis-therapeutics	Preclinical	Lead Optimization
TSC-102-A01	tscan-therapeutics	Preclinical	IND Cleared by FDA
TSC-102-A03	tscan-therapeutics	Preclinical	IND Cleared by FDA
LBL-007	lakeshore-biopharma	Phase 1/2	Active